Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

1-2 years ≤5 visits Efficacy phase (II)Post-Trial Drug Access No Placebo Partially Remote Standard Medicines InjectionEndocrinologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Imcivree

Imcivree is a prescription medicine used to treat rare genetic forms of obesity by helping reduce hunger and manage body weight.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Setmelanotide

Setmelanotide is a substance that reduces excessive hunger and helps promote weight loss in people with certain rare genetic forms of severe obesity.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Universitair Medisch Centrum Utrecht

Pediatric endocrinology

Utrecht, Netherlands

Sponsor: Universitair Medisch Centrum Utrecht

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.